Expression and clinical significance of Lnc RNA HIF1A-AS2 in colorectal cancer tissues

doi:10.3877/cma.j.issn.1674-3946.2020.06.019

Abstract

Abstract:

Objective

To investigate the expression of LncRNA HIF1A-AS2 in colorectal cancer tissues and to explore its clinical significance.

Methods

Clinicopathological data of 114 patients, who were with colorectal cancer from December 2012 to December 2015 and underwent radical resection, were collected, including samples of the cancer tissue and corresponding adjacent tissues (2 cm away from the lesion) and adjacent normal tissues (5 cm away from the edge of the cancer lesion). The relative expression levels of HIF1A-AS2 in colorectal cancer tissues, adjacent tissues and adjacent normal tissues were detected by qRT-PCR. The average expression level of HIF1A-AS2 in 114 enrolled patients was evaluated, and 89 patients with HIF1A-AS2 expression level greater than or equal to the average were divided into the high-expression group, while the rest were divided into the low-expression group. The relationship between HIF1A-AS2 expression and clinicopathological features was analyzed. Kaplan-meier survival curve was usedto analyze the 5-years survival of patients in two groups by using log-rank test. COX proportional risk regression model were used to analyze the independent risk factors for prognosis. A P value of < 0.05 was considered as statistically significant difference.

Results

The relative expression of HIF1A-AS2 in colorectal cancer tissues was higher than that in adjacent tissues and normal tissues (P<0.001). HIF1A-AS2 expression was significantly correlated with clinical stage and degree of differentiation in cancer tissue (P<0.05). The 5-year overall survival rate of the HIF1A-AS2 high-expression group was lower than that of the HIF1A-AS2 low-expression group (log-rank χ²=5.037, P=0.025). COX multi-factor analysis showed that lymph node metastasis, clinical stage Ⅳ, in poorly differentiated, with distant metastasis and HIF1A AS2 significantly high expression were the independent risk factors influencing the prognosis of patients with colorectal cancer (P<0.05).

Conclusion

HIF1A-AS2 is highly expressed in colorectal cancer tissues, which is closely related to clinicopathology and prognosis, and is one of the risk factors for poor prognosis of patients with colorectal cancer.

Key words: Colorectal neoplasms, LncRNA HIF1A-AS2, Gene expression, Prognosis

Yongtao Gao, Ling Wang, Tao Liu, Jiangtao Yuan, Lang Bai, Juan Li, Tiao Qiang. Expression and clinical significance of Lnc RNA HIF1A-AS2 in colorectal cancer tissues[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(06): 600-603.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2020.06.019

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2020/V14/I06/600

Figures/Tables 5

References 16

[1]	王宁，刘硕，杨雷，等.2018全球癌症统计报告解读[J/CD]．肿瘤综合治疗电子杂志，2019, 5(1): 87-97.
[2]	Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm[J]. Cancer research, 2017, 77(15): 3965-3981.
[3]	Hao NB, He YF, Li XQ, et al. The role of miRNA and lncRNA in gastric cancer[J]. Oncotarget, 2017, 8(46): 81572-81582.
[4]	Yue B, Qiu SL, Zhao SL, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis [J]．J Gastroenterol Hepatol，2016, 31(3): 595-603.
[5]	Nie W, Ge HJ, Yang XQ, et al. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p[J]. Cancer Lett, 2016, 371(1): 99-106.
[6]	Zhou M, Sun YY, Sun YF, et al. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer[J]. Oncotarget, 2016, 7(22): 32433-32448.
[7]	Wang YF, Zhang GC, Han J. HIF1A-AS2 predicts poor prognosis and regulates cell migration and invasion in triple-negative breast cancer[J]. J Cell Biochem，2019, 120(6): 10513-10518.
[8]	Chen WM, Huang MD, Kong R，et al.Antisense long noncoding RNA HIF1A-AS2 is upregulated in gastric cancer and associated with poor prognosis[J]. Dig Dis Sci, 2015, 60(6): 1655-1662.
[9]	Lin JG, Shi ZH, Yu ZY, et al. LncRNA HIF1A-AS2 positively affects the progression and EMT formation of colorectal cancer through regulating miR-129-5p and DNMT3A[J]. Biomed Pharmacother, 2018, 98: 433-439.
[10]	Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer[J]. Oncogene, 2017, 36(41): 5661-5667.
[11]	孙跃胜，屈强，潘江华，等．长链非编码RNA在结直肠癌中的作用[J]．中国临床药理学与治疗学，2017, 22(2): 222-227.
[12]	Thrash-Bingham CA, Tartof KD.aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia[J]. J Natl Cancer Inst, 1999, 91(2): 143-151.
[13]	Guo X, Lee SH, Cao PL. The inhibitive effect of sh-HIF1A-AS2 on the proliferation, invasion, and pathological damage of breast cancer via targeting miR-548c-3p through regulating HIF-1α/VEGF pathway in vitro and vivo[J]. Onco Targets Ther，2019, 12: 825-834.
[14]	Chen MW, Zhuang CL, Liu YC, et al. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer[J]. Cancer Lett, 2016, 376(1): 155-164.
[15]	Wu RY, Ruan JH, Sun YJ，et al. Long non-coding RNA HIF1A-AS2 facilitates adipose-derived stem cells (ASCs) osteogenic differentiation through miR-665/IL6 axis via PI3K/Akt signaling pathway[J]. Stem Cell Rese Ther，2018, 9(1): 348.
[16]	Wang XS, Peng L, Gong XJ，et al.LncRNA HIF1A-AS2 promotes osteosarcoma progression by acting as a sponge of miR-129-5p[J]. Aging，2019, 11(24): 11803-11813.

临床病理特征		例数	HIF1A-AS2表达		χ ²/t	P
临床病理特征		例数	高(n＝69)	低(n＝45)	χ ²/t	P
年龄(岁)		-	59.1±7.3	61.4±10.4	1.360	0.088
?	≥60	65	37	28	?	?
?	<60	49	32	17	0.822	0.365
性别		?	?	?	?	?
?	男	62	38	24	?	?
?	女	52	31	21	0.033	0.855
淋巴转移		?	?	?	?	?
?	是	51	34	17	?	?
?	否	63	35	28	1.456	0.228
分化程度		?	?	?	?	?
?	高分化	74	38	36	?	?
?	中-低分化	40	31	9	7.431	0.006
TNM分期		?	?	?	?	?
?	Ⅰ期	36	15	21	?	?
?	Ⅱ期	37	22	15	?	?
?	Ⅲ期	21	15	6	?	?
?	Ⅳ期	20	16	4	9.489	0.023
肿瘤最大径(cm)		-	4.2±2.8	4.8±1.8	1.276	0.102
?	≥5	40	24	16	?	?
?	<5	74	45	29	0.007	0.933
病变部位		?	?	?	?	?
?	结肠	44	30	14	?	?
?	直肠	70	39	31	1.758	0.185
远处转移		?	?	?	?	?
?	M0	84	46	38	?	?
?	M1	30	17	13	0.032	0.857

临床病理特征		例数	HIF1A-AS2表达		χ ²/t	P
临床病理特征		例数	高(n＝69)	低(n＝45)	χ ²/t	P
年龄(岁)		-	59.1±7.3	61.4±10.4	1.360	0.088
?	≥60	65	37	28	?	?
?	<60	49	32	17	0.822	0.365
性别		?	?	?	?	?
?	男	62	38	24	?	?
?	女	52	31	21	0.033	0.855
淋巴转移		?	?	?	?	?
?	是	51	34	17	?	?
?	否	63	35	28	1.456	0.228
分化程度		?	?	?	?	?
?	高分化	74	38	36	?	?
?	中-低分化	40	31	9	7.431	0.006
TNM分期		?	?	?	?	?
?	Ⅰ期	36	15	21	?	?
?	Ⅱ期	37	22	15	?	?
?	Ⅲ期	21	15	6	?	?
?	Ⅳ期	20	16	4	9.489	0.023
肿瘤最大径(cm)		-	4.2±2.8	4.8±1.8	1.276	0.102
?	≥5	40	24	16	?	?
?	<5	74	45	29	0.007	0.933
病变部位		?	?	?	?	?
?	结肠	44	30	14	?	?
?	直肠	70	39	31	1.758	0.185
远处转移		?	?	?	?	?
?	M0	84	46	38	?	?
?	M1	30	17	13	0.032	0.857

临床病理特征	单因素分析
临床病理特征	HR (95% CI)	P
年龄(≥60岁)	0.156(0.743～1.799)	0.521
性别(男)	1.348(0.824～2.203)	0.234
淋巴转移(是)	2.865(1.801～6.854)	0.033
TNM (Ⅳ期)	1.912(2.627～5.780)	0.002
肿瘤最大径(≥5 cm)	1.943(0.982～3.831)	0.354
分化程度(中-低分化)	1.829(1.149～2.911)	0.014
HIF1A-AS2高表达	1.629(1.371～8.159)	0.021
病变部位(结肠)	2.103(0.716～6.205)	0.201
远处转移(M1)	1.348(1.824～2.230)	0.003
临床病理特征	多因素分析
临床病理特征	HR (95% CI)	P
年龄(≥60岁)	-	-
性别(男)	-	-
淋巴转移(是)	2.184(1.473～4.012)	0.018
TNM (Ⅳ期)	1.654(1.124～2.435)	0.011
肿瘤最大径(≥5 cm)	-	-
分化程度(中-低分化)	1.952(2.568～8.700)	0.017
HIF1A-AS2高表达	1.721(1.116～2.656)	0.014
病变部位(结肠)	-	-
远处转移(M1)	1.537(1.007～2.345)	0.046

临床病理特征	单因素分析
临床病理特征	HR (95% CI)	P
年龄(≥60岁)	0.156(0.743～1.799)	0.521
性别(男)	1.348(0.824～2.203)	0.234
淋巴转移(是)	2.865(1.801～6.854)	0.033
TNM (Ⅳ期)	1.912(2.627～5.780)	0.002
肿瘤最大径(≥5 cm)	1.943(0.982～3.831)	0.354
分化程度(中-低分化)	1.829(1.149～2.911)	0.014
HIF1A-AS2高表达	1.629(1.371～8.159)	0.021
病变部位(结肠)	2.103(0.716～6.205)	0.201
远处转移(M1)	1.348(1.824～2.230)	0.003
临床病理特征	多因素分析
临床病理特征	HR (95% CI)	P
年龄(≥60岁)	-	-
性别(男)	-	-
淋巴转移(是)	2.184(1.473～4.012)	0.018
TNM (Ⅳ期)	1.654(1.124～2.435)	0.011
肿瘤最大径(≥5 cm)	-	-
分化程度(中-低分化)	1.952(2.568～8.700)	0.017
HIF1A-AS2高表达	1.721(1.116～2.656)	0.014
病变部位(结肠)	-	-
远处转移(M1)	1.537(1.007～2.345)	0.046

Please choose a citation manager

Content to export